Measuring the efficacy of treatment with neurofeedback method in patients with affective disorders
DOI:
https://doi.org/10.3889/aph.2025.6134Keywords:
affective disorders, antidepressants, neurofeedbackAbstract
Depression affects approximately 280 million people globally, with about 5% of adults experiencing an episode each year, making it a major public health concern. The high prevalence of treatment-resistant depression and the limitations of standard therapies highlight an urgent need for alternative treatments, such as neurofeedback, which has shown promising results in improving depressive symptoms when used alongside conventional pharmacological approaches. Aim of the study: To assess the efficacy of combining neurofeedback training with standard antidepressant therapy in adult patients with affective disorders. Materials and methods: This prospective, randomized study was conducted at the University Clinic for Psychiatry in Skopje, in a 2 month period. It involved a total of 100 outpatients diagnosed with affective disorders (ICD-10 codes F32, F33, F34). Participants were randomized into two groups: the study group (SG) that received both neurofeedback and antidepressant therapy, and the control group (CG) that received antidepressant monotherapy. The HAM-D and HAM-A scales, alongside with a structured psychiatric interview and sociodemographic questionnaire at baseline, were used to assess depressive and anxiety symptoms at baseline, 2 weeks, and 1 month. Data were analyzed with SPSS v23.0, using parametric and non-parametric tests, with significance set at p<0.05. The study received ethics approval, and all participants provided informed consent. Results: At baseline, both groups showed similar levels of depression and anxiety symptoms, with comparable average scores on the HAM-D (SG: 17.98 ± 5.7, CG: 18.42 ± 6.1) and HAMA (SG: 17.98 ± 6.8, CG: 21.36 ± 8.3) scales. At the two-week follow-up, the study group (SG) exhibited significant reductions in both HAM-D and HAMA scores compared to the control group (CG), with a decrease of 2.42 points in HAM-D (or 13.46% vs 0.65%) (p<0.0001) and 2.86 points in HAMA (13.72%, p<0.0001) for the SG, while the CG showed minimal change by 3.78%. At one-month follow-up, the SG continued to demonstrate marked improvement, with HAM-D scores at 14.50 ± 5.5 versus 17.56 ± 6.2 in the CG (p=0.0064) and HAMA scores at 16.82 ± 6.7 in the SG compared to 20.14 ± 8.3 in the CG. Conclusion: The results from the study suggest that neurofeedback, when combined with medication, may enhance both early and sustained symptom improvement of depression and anxiety.
Downloads
References
World Health Organization. Depressive disorder (depression). WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 2024 Nov 10.
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131-4. doi: 10.1176/appi.ajp.158.1.131.
Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on depression: A Lancet-World Psychiatric Association Commission. Lancet. 2022;399(10328):957-1022. doi: 10.1016/S0140-6736(21)02141-3.
Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686. doi: 10.1001/jamanetworkopen.2020.19686.
Albert P. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015;40(4):219-21. doi: 10.1503/jpn.150205.
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21-7. doi: 10.1111/j.1600-0047.2004.00327.x.
Heo M, Murphy CF, Fontaine KR, Bruce ML, Alexopoulos GS. Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050. Int J Geriatr Psychiatry. 2008 Dec;23(12):1266-70. doi: 10.1002/gps.2061. PMID: 18500691; PMCID: PMC3207493.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Major depressive disorder: Developing drugs for treatment. Silver Spring: U.S. Food and Drug Administration; 2018.
European Medicines Agency. Clinical investigation of medicinal products in the treatment of depression – Scientific guideline. Amsterdam: European Medicines Agency; 2018.
McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. doi: 10.1002/wps.21120.
Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. doi: 10.4088/JCP.20m13699.
Xia Z, Yang PY, Chen SL, Zhou HY, Yan C. Uncovering the power of neurofeedback: a meta-analysis of its effectiveness in treating major depressive disorders. Cereb Cortex. 2024;34(6):bhae252. doi: 10.1093/cercor/bhae252.
Patil AU, Lin C, Lee SH, Huang HW, Wu SC, Madathil D, Huang CM. Review of EEG-based neurofeedback as a therapeutic intervention to treat depression. Psychiatry Res Neuroimaging. 2023;329:111591. doi: 10.1016/j.pscychresns.2023.111591.
Boessen R, van den Brink W, de Boer D, Gijsman HJ. Comparing HAMD17 and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. J Affect Disord. 2013;145(3):363-9. doi: 10.1016/j.jad.2012.08.026.
Carrozzino D, Bech P, Patrascu E, Moeller SB, Hofmann B, Tomba E. The Hamilton rating scales for depression: A critical review of clinimetric properties of different versions. Psychother Psychosom. 2020;89(3):133-50. doi: 10.1159/000506879.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959 Mar;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x.
Jeong H, Lee B. Psychometric properties and factor structure of the Hamilton anxiety rating scale among Korean university students during COVID-19. Open Psychol J. 2024;17(1). doi: 10.2174/0118743501268244231108104216.
Asghar J, Arain SM, Hussain J, Bashir H, Iqbal R. A randomized clinical trial comparing two treatment strategies, evaluating the meaningfulness of HAMD rating scale in patients with major depressive disorder. Front Psychiatry. 2022;13:873693. doi: 10.3389/fpsyt.2022.873693.
Latas M, Stefanovski B, Mihaljević-Peleš A, Memić Serdarević A, Pajević I, Radulović NZ, et al. Diagnostic psychiatric and somatic comorbidity in patients with depression in the Western Balkan countries. PLoS ONE. 2024;19(1):e0295754. doi: 10.1371/journal.pone.0295754.
Lee YJ, Kim S, Lee WK, Choi J. Neurofeedback treatment on depressive symptoms and functional recovery in treatment-resistant patients with major depressive disorder: An open-label pilot study. J Korean Med Sci. 2019;34(42):e287. doi: 10.3346/jkms.2019.34.e287.
Liu H. Neurofeedback training intervention for persons with major depression disorder: Reducing depressive symptoms. NeuroQuantology. 2017 Sep 7;15(3). doi: 10.14704/nq.2017.15.3.1091.
Dobbins ICS, Bastos M, Ratis RC, Silva WCFND, Bonini JS. Effects of neurofeedback on major depressive disorder: a systematic review. Einstein (Sao Paulo). 2023 Jul 21;21:eRW0253. doi: 10.31744/einstein_journal/2023RW0253.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandar Risteski, Slavica Arsova, Elizabet Miceva-Velichkoska, Ana Filipce, Stefanija Mitrovska

This work is licensed under a Creative Commons Attribution 4.0 International License.
All wrights are reserved.


